Advertisement

European Journal of Dermatology

, Volume 24, Issue 2, pp 236–241 | Cite as

Clinical implications of distinct metastasizing preferences of different melanoma subtypes

  • Nicola L. Schoenewolf
  • Benedetta Belloni
  • Mathew Simcock
  • Sabina Tonolla
  • Pascale Vogt
  • Ellen Scherrer
  • David Holzmann
  • Reinhard Dummer
Clinical Report

Abstract

Background

The incidence and mortality of malignant melanoma have been rising during the past decades, the latter being due to the high invasion capacity and the metastatic potential of melanoma cells to distant organs.

Objective

We investigated the distribution pattern of melanoma metastases taking into account different clinicopathological subtypes of melanoma.

Methods

We studied 310 stage IV (AJCC 2009) melanoma patients retrospectively with regard to potential correlations between frequency and occurrence of metastasis and the genetic background and pathological/clinical melanoma subtypes. For all patients, the time to distant metastasis (TTDM) and the distribution patterns of metastases were analyzed and correlated to the median survival time.

Results

Superficially Spreading (SSM) and Nodular melanomas (NMM) spread to the brain more frequently than Acrolentiginous (ALM) and Mucosal (MM) melanomas (p = 0.0012). The preference to affect the skeleton was significantly higher for ALM and MM in comparison to SSM and NMM (p = 0.0049). Lentigo maligna (LMM) tumors showed a significantly lower metastatic spread to distant lymph nodes (p = 0.0159). BRAF mutant versus wildtype tumors showed no significant differences concerning localization of metastasis but patients with BRAF mutant tumors were significantly younger at primary diagnosis and had a significantly shorter stage IV survival (p = 0.0106).

Conclusion

This study shows a clear distinction of melanoma subtypes with regard to metastasizing preferences. Further knowledge about melanoma subtype specific characteristics, including molecular markers predictive of homing preferences, may help to understand and manage this heterogeneous disease in terms of prognosis and follow-up procedures.

Key words

predictive metastatic patterns melanoma metastasis melanoma subtypes prognostic factors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998;58:2170–2175.PubMedGoogle Scholar
  2. 2.
    Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340–4346.PubMedCrossRefGoogle Scholar
  3. 3.
    Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135–2147.PubMedCrossRefGoogle Scholar
  4. 4.
    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199–6206.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002;147:62–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Reintgen DS, Cox C, Slingluff CL Jr., Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992;28:45–49.PubMedCrossRefGoogle Scholar
  7. 7.
    Bulliard J, Panizzon R, Levi F. Epidemiologie und Prävention des Hautmelanoms in der Schweiz. Schweiz Med Forum 2009;9:314–318.Google Scholar
  8. 8.
    Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578–583.PubMedCrossRefGoogle Scholar
  9. 9.
    Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 1999;38:549–557.PubMedCrossRefGoogle Scholar
  10. 10.
    de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983;43:3427–3433.PubMedGoogle Scholar
  11. 11.
    Tejera-Vaquerizo A, Barrera-Vigo MV, Fernandez-Canedo I, et al. [Longitudinal study of different metastatic patterns in the progression of cutaneous melanoma]. Actas Dermosifiliogr 2007;98:531–538.PubMedCrossRefGoogle Scholar
  12. 12.
    Zakrzewski J, Geraghty LN, Rose AE, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 2011;117:1711–1720.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Jakob JA, Bassett JRL, Ng CS, et al. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. ASCO Abstract ID (Temp Abst ID): 8500(76931) 2011.Google Scholar
  14. 14.
    Thomas AJ, Erickson CA. The making of a melanocyte: the specification of melanoblasts from the neural crest. Pigment Cell Melanoma Res 2008;21:598–610.PubMedCrossRefGoogle Scholar
  15. 15.
    Mohammad KS, Javelaud D, Fournier PG, et al. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 2011;71:175–184.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011;364:2507–2516.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–954.PubMedCrossRefGoogle Scholar
  18. 18.
    Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. J Clin Oncol 2011;29:1239–1244.PubMedCrossRefGoogle Scholar
  19. 19.
    Tan A, Moodie K, Kerr L, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010;102:1219–1223.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Schoenewolf NL, Urosevic-Maiwald M, Dummer R. Tumor heterogeneity of mucosal melanomas during treatment with imatinib. Br J Dermatol 2011;165:419–424.PubMedCrossRefGoogle Scholar
  21. 21.
    Koh HK, Michalik E, Sober AJ, et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol 1984;2:994–1001.PubMedGoogle Scholar

Copyright information

© John Libbey Eurotext 2014

Authors and Affiliations

  • Nicola L. Schoenewolf
    • 1
  • Benedetta Belloni
    • 1
  • Mathew Simcock
    • 2
  • Sabina Tonolla
    • 1
  • Pascale Vogt
    • 1
  • Ellen Scherrer
    • 1
  • David Holzmann
    • 3
  • Reinhard Dummer
    • 1
  1. 1.Department of DermatologyUniversity Hospital of ZurichZurichSwitzerland
  2. 2.SAKK Coordinating CenterBernSwitzerland
  3. 3.Department of OtorhinolaryngologyUniversity Hospital of ZurichZurichSwitzerland

Personalised recommendations